Document is current
Any future updates will be listed below
-
Authors
Xiong, Wei https://orcid.org/0000-0003-2126-8535
Yamashita, Yugo https://orcid.org/0000-0003-2583-1321
Morimoto, Takeshi
Takase, Toru
Hiramori, Seiichi
Kim, Kitae
Oi, Maki
Akao, Masaharu
Kobayashi, Yohei
Chen, Po-Min
Murata, Koichiro
Tsuyuki, Yoshiaki
Nishimoto, Yuji
Sakamoto, Jiro
Togi, Kiyonori
Mabuchi, Hiroshi
Takabayashi, Kensuke
Kato, Takao
Ono, Koh
Kimura, Takeshi
,
-
Funding
Funding for this research was provided by:
International Talent Training Program of Shanghai Xinhua Hospital (2023YGJRC04)
Research Institute for Production Development, Kyoto, Japan (Research Institute for Production Development, Kyoto, Japan)
Mitsubishi Tanabe Pharma Corporation (Mitsubishi Tanabe Pharma Corporation)
- License Information
-
More Information
Article History
Accepted: 2 June 2024
First Online: 9 July 2024
Declarations
:
: Dr. Yamashita received lecture fees from Daiichi-Sankyo, Bristol-Myers Squibb, Pfizer, and Bayer Healthcare. Dr Morimoto reports lecturer’s fees from Bristol-Myers Squibb, Daiichi Sankyo, Japan Lifeline, Kowa, Kyocera, Novartis, and Toray; manuscript fees from Bristol-Myers Squibb and Kowa; advisory board for Sanofi. Dr. Akao received lecture fees from Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim, Bayer Healthcare and Daiichi-Sankyo. Dr. Nishimoto received lecture fees from Daiichi-Sankyo, Bristol-Myers Squibb, Pfizer, and Bayer Healthcare. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
: The e-Appendixes, e-Figures, and e-Table can be found in the Supplemental Materials section of the online article.
